<ref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="B159"><label>159</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>VKC</given-names></name><name><surname>Al-Badriyeh</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>SF</given-names></name><name><surname>Yiu</surname><given-names>HHE</given-names></name><etal/></person-group>. <article-title>Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis</article-title>. <source>J Pharm Policy Pract</source>. (<year>2024</year>) <volume>17</volume>:<fpage>2375269</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/20523211.2024.2375269</pub-id>, PMID: <?supplied-pmid 39027009?><pub-id pub-id-type="pmid">39027009</pub-id>
</mixed-citation></ref>